Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 10/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25639719 | 0.86 | ACVRL1 (0.51) | ACVRL1PIK3CDRIPK1AXLMERTK | |
| SCHEMBL22676013 | 0.86 | ACVRL1 (0.50) | ACVRL1PIK3CDRIPK1AXLMERTK | |
| SCHEMBL22677099 | 0.82 | RIPK1 (0.37) | PIK3CDRIPK1 | |
| SCHEMBL25639720 | 0.70 | RIPK1 (0.38) | PIK3CDRIPK1 | |
| SCHEMBL59888 | 0.67 | FLT3 (0.52) | ACVRL1RIPK1AXL | |
| SCHEMBL27768094 | 0.66 | ACVRL1 (0.54) | ACVRL1PIK3CDAXLMERTK | |
| SCHEMBL22676814 | 0.66 | FGFR1 (0.40) | ACVRL1RIPK1AXLMERTK | |
| SCHEMBL22676440 | 0.66 | AURKA (0.37) | RIPK1AXLMERTK | |
| SCHEMBL25715746 | 0.66 | PIK3CD (0.40) | ACVRL1PIK3CDRIPK1 | |
| SCHEMBL22676433 | 0.65 | NAMPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3968999-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| EP-3968999-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | ACVRL1 207/4885PIK3CD 254/4885RIPK1 1262/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | ACVRL1 207/4885PIK3CD 254/4885RIPK1 1262/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | ACVRL1 207/4885PIK3CD 254/4885RIPK1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.